"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves luspatercept-aamt (Reblozyl) for anemia in patients with beta thalassemia

08 Nov 2019 2:21 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl; Celgene) for treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software